Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN

Biotechnology

Healthcare
$945.53 -0.90%

-$5.45 today

Market cap
$97.80B
Beta
0.24
P/E (TTM)
14.2
EPS (TTM)
$42.53
Dividend yield
0.60%
52W Low $506.38High $821.11

Volume 0.70M

Average 0.91M

REGN Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Regeneron Pharmaceuticals, Inc.NASDAQ: REGN

Operating Margin · Q2 FY2026 · quarter ended Jun 2026

Operating margin widens to 33.1%

Operating margin was 33.1% in Q2 FY2026, up 3.7 pp from a year earlier. On a trailing-twelve-month basis it was 25.6%, down 1.5 pp year over year. Over 3 fiscal years it narrowed by 19.3 pp.

Context

  • Operating margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether operating margin reaches the consensus estimate from 19 analysts of 44.2% for the fiscal year ending Dec 2026, up from 24.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
33.1%+15.3 pp QoQ
Last fiscal yearDec 2025
24.9%-3.2 pp YoY
LTMJun 2026
25.6%-1.5 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+3.7 pp+15.3 pp+11.5 pp
1 year-3.2 pp+19.2 pp+22.4 pp
3 years-19.3 pp+18.4 pp+37.7 pp
5 years+20.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
24.9%
Year-over-year change
-3.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How REGN compares with its peers on the latest reported figures

  • REGN's LTM Jun 2026 operating margin of 25.6% is the 4th highest of the 9 companies compared; the peer median is 18.2%.
  • Its year-over-year change of -1.5 pp is the 4th highest of 8, against a peer median of -11.3 pp.
  • Over three fiscal years its change of -19.3 pp compares with a peer median of -8.3 pp.
REGN Competitors Peer median
Operating Margin for REGN and competitors
Company Period LTM level YoY 3-year change
AMGNAmgen Inc.LTM Jun 202633.2% +9.7 pp-7.3 pp
GMABGenmab A/SLTM Jun 202632.3% —-9.6 pp
NVSNovartis AGLTM Jun 202630.5% +0.3 pp+12.9 pp
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 202625.6% -1.5 pp-19.3 pp
AZNAstraZeneca PLCLTM Sep 202623.7% +1.6 pp+14.9 pp
BIIBBiogen Inc.LTM Jun 202612.8% -11.3 pp-9.3 pp
GILDGilead Sciences, Inc.LTM Jun 2026-4.9% -32.8 pp+12.9 pp
OCULOcular Therapeutix, Inc.LTM Mar 2026-575.4% -233.3 pp-368.3 pp
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026-3700.9% -3412.9 pp-535.3 pp
Peer median (excluding REGN) 18.2%-11.3 pp-8.3 pp

Competitors are the stored peer set for REGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue16.07B12.17B13.12B14.2B14.34B
Cost of Revenue2.72B1.71B2.24B1.97B2.1B
Gross Profit13.35B10.47B10.87B12.23B12.24B
Gross Margin83.1%86.0%82.9%86.1%85.4%
Research & Development2.62B3.06B3.99B5.23B5.85B
Selling, General & Admin1.82B2.12B2.54B2.95B2.7B
Operating Expenses4.4B5.08B6.52B8.24B8.66B
Depreciation & Amortization286.2M341.4M421M482.9M543.7M
EBITDA9.67B5.26B4.69B5.32B5.82B
EBITDA Margin60.2%43.2%35.8%37.4%40.6%
Operating Income8.95B5.39B4.35B3.99B3.58B
Operating Margin55.7%44.2%33.2%28.1%24.9%
Interest Income0160.1M495.9M711.4M716.8M
Interest Expense57.3M59.4M73M55.2M43.8M
Other Income / Expenses379M(526.8M)(149.3M)789.2M1.65B
Income Before Tax9.33B4.86B4.2B4.78B5.23B
Pre-Tax Margin58.0%39.9%32.0%33.7%36.5%
Income Tax Expense1.25B520.4M245.7M367.3M725.8M
Net Income8.08B4.34B3.95B4.41B4.5B
Net Margin50.2%35.6%30.1%31.1%31.4%
EPS (Basic)76.4040.5137.0540.9043.07
EPS (Diluted)71.9738.2234.7738.3441.48
Weighted Avg Shares105.7M107.1M106.7M107.9M104.6M
Weighted Avg Shares (Diluted)112.2M113.5M113.7M115.1M108.6M

Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN

Intrinsic Alpha fair value

Locked

Current Price

$945.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.